Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
about
HIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchA Blueprint for HIV Vaccine DiscoveryA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineHIV-1 neutralizing antibodies: understanding nature's pathwaysThe Antibody Response against HIV-1CryoEM visualization of an adenovirus capsid-incorporated HIV antigenDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionAntiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory AntibodiesRecent Insights into the HIV/AIDS Pandemic.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.New technologies for influenza vaccines.Controlling the HIV/AIDS epidemic: current status and global challengesAggregate complexes of HIV-1 induced by multimeric antibodies.Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women.Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.Synthetic carbohydrate antigens for HIV vaccine design.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Virulence and pathogenesis of HIV-1 infection: an evolutionary perspectiveMicrodevices for examining immunological responses of single cells to HIVDesign of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccinationB-cell-lineage immunogen design in vaccine development with HIV-1 as a case studyNeutralisation of HIV-1 cell-cell spread by human and llama antibodies.Designing a soluble near full-length HIV-1 gp41 trimer.Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure.A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilizationChimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.Selection of intracellular single-domain antibodies targeting the HIV-1 Vpr protein by cytoplasmic yeast two-hybrid system.Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-DependentThe HIV-1 epidemic: low- to middle-income countries.Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising.Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and BioinformaticsThe role of evolutionarily conserved germ-line DH sequence in B-1 cell development and natural antibody production.The changing face of HIV vaccine research.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design
P2860
Q26746070-3EA3FDD8-809F-4071-A732-617BC275E72DQ26829865-2E4EC105-E0BD-491F-A63A-3C260527375AQ26830360-70932C02-EB9A-49AB-A772-6D3AD363C422Q27000480-53074024-DB7C-4BCE-A160-915FE8D54BC9Q27000889-DE5A0C75-C8D8-4EBA-B5D5-4C7927507EF3Q27335395-BD14992F-6300-4B80-A0F4-CD5308D0F485Q27654848-8D511F55-88CE-4527-A676-991E60ABBFE8Q27676864-514FF151-5FC6-49DB-A449-94DA7A50B8F5Q28066335-5E909C3E-365E-46C8-B0EF-B8C1BCF0ABCDQ30235024-192748DF-FE36-455D-9501-4CA2461B6251Q30353580-6BDBD963-A828-4F41-A2C1-31E254679B2CQ30358736-57259B45-1D0D-4E48-92F6-6B725C31CDBEQ30411859-887EDFB4-6FE7-4C1A-B0EC-1AA6A65D1DD7Q30420558-9758612B-9894-45C2-AE7B-BC2B784E6F89Q30428633-C8E3A2DD-33F4-411D-ABB7-27DB801ABA62Q33588543-060602AF-BE6A-48C5-9185-C0BD7D544E42Q33624872-316CA79F-DD83-4950-ABB7-30AD1C8FF7DCQ33855697-A90F0C17-BB03-4EE2-956F-CA60E4482DF6Q33909079-87239B9C-D39A-497C-BFBE-AC27FFEF228EQ34016706-0C2BC033-410E-41E8-80C0-C2ABCB329526Q34040248-8FC75ABE-77D8-4E03-9303-CC62F16AE6BAQ34065197-F27E96BB-E7E4-4A9B-9CD0-970D81E04081Q34074750-B326609E-6615-4171-BD0E-122499C6B732Q34273373-B489269A-C63F-4903-9904-45B0F339BC5FQ34304203-7D7D411A-A8FF-4C90-9A60-D0F00613EAB5Q34489464-51A3BE9C-8FB4-4180-A40C-5F567E00F47AQ34650084-0EB89FA7-CF41-4104-9589-34E53ACB5B81Q34919985-B5FD8135-3510-4152-924F-85E0E2BF7CD7Q34988326-FB6347F0-4702-4216-91FD-5E165EC303C8Q35462984-0047FEF4-5734-4ED6-A3B1-9DCB5D7F97E2Q35580892-7694AA81-4C0E-451C-A24A-A77DC224F439Q35667479-7C3CAE1C-5AAB-47D3-9949-CB4A69EFABFDQ35686912-47B8A725-B9D9-48A8-BC7A-21D14431765AQ35765737-CB655277-8500-4215-8FB4-57AA335CDF73Q35973601-1E993A17-56DC-444D-A709-0577574B9010Q36079024-0ED5E357-1BF2-4E94-A909-8451E331F0B7Q36231944-F85E65BE-B309-422B-8329-A330A1BFC889Q36373351-1D7935F7-62BC-424C-A82C-B889B6137CB1Q36404101-8CB329B3-0BD1-4A65-880F-760CC1444767Q36447540-1E04143B-0F3C-4764-BBCA-752CA98576C7
P2860
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@ast
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@en
type
label
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@ast
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@en
prefLabel
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@ast
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@en
P2860
P1476
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
@en
P2093
Peter D Kwong
P2860
P304
P356
10.1101/CSHPERSPECT.A007278
P577
2011-09-01T00:00:00Z